vs
aTYR PHARMA INC(ATYR)与Cardio Diagnostics Holdings, Inc.(CDIO)财务数据对比。点击上方公司名可切换其他公司
Cardio Diagnostics Holdings, Inc.自由现金流更多($-5.9M vs $-62.1M)
aTyr Pharma是一家上市生物治疗企业,专注于研究氨酰tRNA合成酶的胞外功能与相关信号通路,深耕tRNA合成酶相关领域的创新生物药物研发,致力于开发相关新型疗法以满足未被满足的医疗需求。
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业,开发并商业化整合遗传与表观遗传技术的诊断检测产品,可早期识别冠心病、心力衰竭等心血管疾病,主要服务美国市场的医疗机构、临床实验室与患者。
ATYR vs CDIO — 直观对比
营收规模更大
CDIO
是对方的Infinity倍
$0
自由现金流更多
CDIO
多$56.1M
$-62.1M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $0 | $3.6K |
| 净利润 | — | — |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | — | -21.2% |
| 净利润同比 | 6.7% | 3.6% |
| 每股收益(稀释后) | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ATYR
CDIO
| Q4 25 | $0 | $3.6K | ||
| Q3 25 | $190.0K | $2.9K | ||
| Q2 25 | $0 | $7.5K | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $0 | $4.5K | ||
| Q3 24 | $0 | $6.6K | ||
| Q2 24 | $0 | $7.9K | ||
| Q1 24 | $235.0K | $15.9K |
净利润
ATYR
CDIO
| Q4 25 | — | — | ||
| Q3 25 | $-25.7M | $-1.7M | ||
| Q2 25 | $-19.5M | $-1.7M | ||
| Q1 25 | $-14.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-17.3M | $-1.4M | ||
| Q2 24 | $-16.3M | $-1.3M | ||
| Q1 24 | $-15.5M | $-4.2M |
营业利润率
ATYR
CDIO
| Q4 25 | — | — | ||
| Q3 25 | -14076.3% | -59950.9% | ||
| Q2 25 | — | -22457.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -21412.9% | ||
| Q2 24 | — | -16295.6% | ||
| Q1 24 | -7079.1% | -26105.3% |
净利率
ATYR
CDIO
| Q4 25 | — | — | ||
| Q3 25 | -13549.5% | -60053.8% | ||
| Q2 25 | — | -22517.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -21467.6% | ||
| Q2 24 | — | -16365.9% | ||
| Q1 24 | -6591.9% | -26140.0% |
每股收益(稀释后)
ATYR
CDIO
| Q4 25 | — | — | ||
| Q3 25 | $-0.26 | $-0.98 | ||
| Q2 25 | $-0.22 | $-0.97 | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.23 | $-1.73 | ||
| Q2 24 | $-0.23 | $-1.71 | ||
| Q1 24 | $-0.23 | $-5.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $10.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $67.5M | $7.0M |
| 总资产 | $93.0M | $7.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势,按日历期对齐
现金及短期投资
ATYR
CDIO
| Q4 25 | $10.7M | — | ||
| Q3 25 | $85.2M | — | ||
| Q2 25 | $17.2M | — | ||
| Q1 25 | $10.4M | — | ||
| Q4 24 | $11.1M | — | ||
| Q3 24 | $11.5M | — | ||
| Q2 24 | $6.8M | — | ||
| Q1 24 | $6.8M | — |
股东权益
ATYR
CDIO
| Q4 25 | $67.5M | $7.0M | ||
| Q3 25 | $80.2M | $8.2M | ||
| Q2 25 | $74.8M | $9.7M | ||
| Q1 25 | $75.0M | — | ||
| Q4 24 | $70.0M | $9.6M | ||
| Q3 24 | $65.3M | $3.7M | ||
| Q2 24 | $81.6M | $3.1M | ||
| Q1 24 | $84.5M | $3.0M |
总资产
ATYR
CDIO
| Q4 25 | $93.0M | $7.8M | ||
| Q3 25 | $106.7M | $8.8M | ||
| Q2 25 | $101.5M | $10.4M | ||
| Q1 25 | $97.2M | — | ||
| Q4 24 | $96.8M | $10.6M | ||
| Q3 24 | $91.6M | $4.5M | ||
| Q2 24 | $105.9M | $4.0M | ||
| Q1 24 | $113.3M | $4.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-62.0M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | $-62.1M | $-5.9M |
| 自由现金流率自由现金流/营收 | — | -166361.5% |
| 资本支出强度资本支出/营收 | — | 5269.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-14.3M |
8季度趋势,按日历期对齐
经营现金流
ATYR
CDIO
| Q4 25 | $-62.0M | $-5.7M | ||
| Q3 25 | $-20.5M | $-1.4M | ||
| Q2 25 | $-13.9M | $-1.6M | ||
| Q1 25 | $-15.4M | — | ||
| Q4 24 | $-69.1M | $-5.0M | ||
| Q3 24 | $-13.2M | $-1.2M | ||
| Q2 24 | $-20.4M | $-1.2M | ||
| Q1 24 | $-22.4M | $-1.2M |
自由现金流
ATYR
CDIO
| Q4 25 | $-62.1M | $-5.9M | ||
| Q3 25 | $-20.5M | $-1.6M | ||
| Q2 25 | $-13.9M | $-1.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | $-69.2M | $-5.2M | ||
| Q3 24 | $-13.2M | $-1.2M | ||
| Q2 24 | $-20.5M | $-1.4M | ||
| Q1 24 | $-22.4M | $-1.3M |
自由现金流率
ATYR
CDIO
| Q4 25 | — | -166361.5% | ||
| Q3 25 | -10796.3% | -54509.7% | ||
| Q2 25 | — | -21273.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -115422.6% | ||
| Q3 24 | — | -17942.3% | ||
| Q2 24 | — | -17513.3% | ||
| Q1 24 | -9530.6% | -7866.9% |
资本支出强度
ATYR
CDIO
| Q4 25 | — | 5269.1% | ||
| Q3 25 | 19.5% | 5703.5% | ||
| Q2 25 | — | 250.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4759.9% | ||
| Q3 24 | — | 353.3% | ||
| Q2 24 | — | 2133.4% | ||
| Q1 24 | 7.2% | 125.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图